Richard Law
Stock Analyst at Goldman Sachs
(2.75)
# 1,734
Out of 4,814 analysts
59
Total ratings
66.67%
Success rate
23.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $23.83 | +25.89% | 1 | Apr 8, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $6 → $4 | $3.15 | +26.98% | 2 | Mar 4, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $29 → $15 | $6.33 | +136.97% | 2 | Mar 3, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $42 → $36 | $18.29 | +96.83% | 2 | Mar 3, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $82 → $73 | $37.90 | +92.61% | 3 | Feb 27, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $28 → $24 | $13.26 | +81.06% | 6 | Feb 13, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $43.00 | +69.77% | 1 | Nov 21, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $25 → $31 | $13.10 | +136.64% | 2 | Sep 12, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $24 | $4.26 | +463.38% | 4 | Apr 2, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $4.43 | +148.31% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $31 | $4.61 | +573.18% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $16.25 | +189.23% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $37.76 | +66.84% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $26.00 | +42.31% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $7.27 | +946.11% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $1.29 | +989.49% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $8.60 | +609.30% | 4 | May 8, 2023 |
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $23.83
Upside: +25.89%
Silence Therapeutics
Mar 4, 2025
Maintains: Sell
Price Target: $6 → $4
Current: $3.15
Upside: +26.98%
Rocket Pharmaceuticals
Mar 3, 2025
Maintains: Neutral
Price Target: $29 → $15
Current: $6.33
Upside: +136.97%
Celldex Therapeutics
Mar 3, 2025
Maintains: Neutral
Price Target: $42 → $36
Current: $18.29
Upside: +96.83%
MoonLake Immunotherapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $82 → $73
Current: $37.90
Upside: +92.61%
Mineralys Therapeutics
Feb 13, 2025
Maintains: Buy
Price Target: $28 → $24
Current: $13.26
Upside: +81.06%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $43.00
Upside: +69.77%
Viridian Therapeutics
Sep 12, 2024
Maintains: Buy
Price Target: $25 → $31
Current: $13.10
Upside: +136.64%
Olema Pharmaceuticals
Apr 2, 2024
Initiates: Buy
Price Target: $24
Current: $4.26
Upside: +463.38%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $4.43
Upside: +148.31%
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $4.61
Upside: +573.18%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $16.25
Upside: +189.23%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $37.76
Upside: +66.84%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $26.00
Upside: +42.31%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $7.27
Upside: +946.11%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $1.29
Upside: +989.49%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $8.60
Upside: +609.30%